Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other Accumulated Expenses (2019 - 2025)

Aytu Biopharma (AYTU) has disclosed Other Accumulated Expenses for 7 consecutive years, with $216000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 92.86% to $216000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $216000.0, a 92.86% decrease, with the full-year FY2025 number at $1.9 million, down 17.43% from a year prior.
  • Other Accumulated Expenses was $216000.0 for Q4 2025 at Aytu Biopharma, down from $221000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $9.1 million in Q1 2024 to a low of $216000.0 in Q4 2025.
  • A 5-year average of $3.9 million and a median of $3.2 million in 2021 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: soared 619.37% in 2021, then plummeted 97.2% in 2025.
  • Aytu Biopharma's Other Accumulated Expenses stood at $3.2 million in 2021, then grew by 15.35% to $3.7 million in 2022, then crashed by 30.87% to $2.5 million in 2023, then grew by 19.64% to $3.0 million in 2024, then tumbled by 92.86% to $216000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Other Accumulated Expenses are $216000.0 (Q4 2025), $221000.0 (Q3 2025), and $1.9 million (Q2 2025).